Rosetta Genomics Identifies Hundreds of Novel Human microRNAs, Study Published in Nature Genetics Shows - Novel approach identifies 89 novel new human microRNAs, nearly doubling

the number of human microRNAs sequenced to date, and predicts number

exceeds 800.



- First report of large number of primate specific microRNA, postulated

to play an important role in differentiation and evolution.



    REHOVOT, Israel, June 21 /PRNewswire/ -- In a study published online this
 week and to be published as a cover story in the July issue of Nature
 Genetics, Rosetta Genomics' scientists report identification of hundreds of
 human microRNA genes, including the first report of primate specific
 microRNAs. Using a novel methodology, the researchers successfully cloned and
 sequenced 89 human microRNAs, nearly doubling the number sequenced in man to
 date.
     MicroRNAs are a recently discovered class of tiny regulatory genes,
 comprised in the 98% of the genome that does not encode proteins, which until
 recently were considered 'Junk DNA'. Numerous recent studies have shown
 microRNA genes, far from being 'junk', are in fact of central importance,
 regulating at least 30% of all proteins, and involved in a wide range of
 diseases, including diabetes, obesity, viral diseases, and various types of
 cancer.
     "The finding of large numbers of primate specific microRNAs is exciting
 because it supports the notion that microRNAs may indeed play an important
 role in the evolution of complexity of higher organisms," said Aaron
 Ciechanover, Nobel prize laureate 2004, and Chairman of Rosetta Genomics'
 Scientific Advisory Board. "We believe that these genes may serve as an
 important basis for next generation diagnostics and therapeutics."
     "We are extremely pleased to report our success in nearly doubling the
 number of human microRNAs sequenced to date, results which we believe
 establish Rosetta Genomics as a leading player in discovery of microRNA
 genes," said Isaac Bentwich MD, founder and chairman of Rosetta Genomics and
 lead investigator of the study. "We are now aggressively pursuing partnerships
 for development of diagnostics and therapeutics based on this huge group of
 novel microRNAs."
 
     About microRNAs
     MicroRNAs are a recently discovered group of non-protein-coding regulatory
 genes, shown to be involved in a wide range of diseases in addition to
 neuronal and stem-cell differentiation. MicroRNAs currently are an intensely
 researched area, and are believed potentially to be the basis for a new class
 of therapeutic and diagnostic products.
 
     About Rosetta Genomics
     Rosetta Genomics is a privately held genomics company, pioneering the
 discovery and commercialization of microRNAs - a novel group of regulatory
 genes, shown to be involved in a wide range of diseases including diabetes,
 obesity and various types of cancer. Rosetta has discovered and filed patents
 for the majority of microRNAs found to date, and is in the process of
 developing diagnostics and therapeutics based on these microRNAs, by both
 internal development and collaborative partnerships.
 
      Rachel Spielman              Sharon Kaspi
      Ruder Finn                   Rosetta Genomics Media Relations
      Tel    +1 212 583 2714       Tel    +1 201 255 5900
      Mobile +1 646 872 2985       Mobile +1 201 255 5914
      spielmanr@ruderfinn.com      sharon@rosettagenomics.com
 
 

SOURCE Rosetta Genomics

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.